SeaStar Medical Holding Corporation filings document a medical-device issuer with common stock and publicly listed warrants, registration activity, governance matters, and material events. Securities Act registration statements describe delayed or continuous securities offerings and related capital-structure disclosures, while proxy materials cover annual-meeting voting procedures, board and governance matters, and compensation disclosures.
Current reports on Form 8-K record operating results, QUELIMMUNE and SCD business updates furnished with earnings releases, Nasdaq listing-compliance matters, officer appointments and compensation arrangements, and completed litigation-status disclosures. The filings also frame disclosure topics tied to QUELIMMUNE commercialization, SCD clinical development, FDA post-approval obligations, risk factors, and financing activity.
SeaStar Medical Holding Corporation (NASDAQ: ICU) has filed an S-1/A amendment for a significant securities offering, including:
The offering comprises:
- Up to 5,149,860 shares of common stock with accompanying Series A and B warrants
- Alternative option of 5,149,860 pre-funded warrants with accompanying Series A and B warrants
- 297,035 placement agent warrants
- Total of 15,746,615 shares issuable upon exercise of all warrants
Key terms include an assumed offering price of $0.9709 per share, with Series A warrants having a 5-year term and Series B warrants an 18-month term. H.C. Wainwright & Co. is acting as exclusive placement agent, receiving a 7% cash fee and 1% management fee. The company, classified as a smaller reporting and emerging growth company, recently completed a 1-for-25 reverse stock split in June 2024. The offering will terminate on July 18, 2025, unless terminated earlier.